Adipose-derived stem cells and lattices

• US 20050282275A1
• Filed: 08/24/2005
• Published: 12/22/2005
• Est. Priority Date: 03/10/1999
• Status: Abandoned Application

• Current Assignee: Regents of the University of California (University of California), University of Pittsburgh of The Commonwealth System of Higher Education
• Original Assignee: Regents of the University of California (University of California), University of Pittsburgh of The Commonwealth System of Higher Education
• Inventors: Llull, Ramon, Benhaim, Prosper, Hedrick, Marc H., Katz, Adam J., Zhu, Min, Lorenz, Hermann Peter, Futrell, J. William
• Application Number:
  US11/211,114
• Publication Number:
  US 20050282275A1
• Time in Patent Office: Days
• US Class Current: 435/366
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2500/38 Vitamins
• CPC Class Codes: C12N 2500/42 Organic phosphate, e.g. beta glycerophosphate
• CPC Class Codes: C12N 2501/01 Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
• CPC Class Codes: C12N 2501/33 Insulin together with transferrin C12N2500/25; Insulin-like growth factors C12N2501/105
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 2502/1305 Adipocytes
• CPC Class Codes: C12N 2506/1384 from adipose-derived stem cells [ADSC], from adipose stromal stem cells
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 2533/90 Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
• CPC Class Codes: C12N 5/0068 General culture methods using substrates for specific animal cell type C12N5/06
• CPC Class Codes: C12N 5/0647 Haematopoietic stem cells; Uncommitted or multipotent progenitors
• CPC Class Codes: C12N 5/0652 Cells of skeletal and connective tissues; Mesenchyme
• CPC Class Codes: C12N 5/0653 Adipocytes; Adipose tissue
• CPC Class Codes: C12N 5/0654 Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
• CPC Class Codes: C12N 5/0655 : Chondrocytes; Cartilage
• CPC Class Codes: C12N 5/0658 : Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
• CPC Class Codes: C12N 5/0667 : Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

Abstract

The present invention provides adipose-derived stem cells and lattices. In one aspect, the present invention provides a lipo-derived stem cell substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The invention also provides a method of isolating stem cells from adipose tissues. The cells can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the cells can be expanded and cultured to produce hormones and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides a lipo-derived lattice substantially devoid of cells, which includes extracellular matrix material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures.

Claims

1. A mammalian lipo-derived stem cell substantially free of mature adipocytes, which can be cultured in DMEM+about 10% fetal bovine serum without differentiating and which has two or more developmental phenotypes selected from the group of developmental phenotypes consisting of adipogenic, chondrogenic, cardiogenic, dermatogenic, hematopoetic, hemangiogenic, myogenic, nephrogenic, neurogenic, neuralgiagenic, urogenitogenic, osteogenic, pericardiogenic, peritoneogenic, pleurogenic, splanchogenic, and stromal developmental phenotypes.

2. The cell of claim 1, which can be cultured in DMEM+about 10% fetal bovine serum for at least 15 passages without differentiating.

3. The cell of claim 1, which is human.

4. The cell of claim 1, which is genetically modified.

5. The cell of claim 1, which has a cell-surface bound intercellular signaling moiety.

6. The cell of claim 1, which secretes a hormone.

7. The cell of claim 6, wherein the hormone is selected from the group of hormones consisting of cytokines and growth factors.

8. A defined cell population comprising a cell of claim 1.

9. The defined cell population of claim 8, which is heterogeneous.

10. The defined cell population of claim 9, further comprising a stem cell selected from the group of cells consisting of neural stem cells (NSC), hematopoetic stem cells (HPC), embryonic stem cells (ESC) and mixtures thereof.

11. The defined cell population of claim 8, which consists essentially of said cells.

12. The defined cell population of claim 8, which is substantially homogenous.

13. The defined cell population of claim 12, which is clonal.

14. A composition comprising the cell of claim 1 and a biologically compatible lattice.

15. A composition comprising the population of claim 8 and a biologically compatible lattice.

16. The composition of claim 15, wherein the lattice comprises polymeric material.

17. The composition of claim 16, wherein the polymeric material is formed of polymer fibers as a mesh or sponge.

18. The composition of claim 16, wherein the polymeric material comprises monomers selected from the group of monomers consisting of glycolic acid, lactic acid, propyl fumarate, caprolactone, hyaluronan, hyaluronic acid and combinations thereof.

19. The composition of claim 16, wherein the polymeric material comprises proteins, polysaccharides, polyhydroxy acids, polyorthoesters, polyanhydrides, polyphosphazenes, synthetic polymers or combinations thereof.

20. The composition of claim 16, wherein the polymeric material is a hydrogel formed by crosslinking of a polymer suspension having the cells dispersed therein.

21. The composition of claim 16, wherein the lattice further comprises a hormone selected from the group of hormones consisting of cytokines and growth factors.

22. A method of obtaining a genetically-modified cell comprising exposing the cell of claim 1 to a gene transfer vector comprising a nucleic acid including a transgene, whereby the nucleic acid is introduced into the cell under conditions whereby the transgene is expressed within the cell.

23. The method of claim 22, wherein the transgene encodes a protein conferring resistance to a toxin.

24. A method of delivering a transgene to an animal comprising (a) obtaining a genetically-modified cell in accordance with claim 23 and (b) introducing the cell into the animal, such that the transgene is expressed in vivo.

25. A method of differentiating the cell of claim 1, comprising culturing the cell in a morphogenic medium under conditions sufficient for the cell to differentiate.

26. The method of claim 25, wherein the medium is an adipogenic, chondrogenic, cardiogenic, dermatogenic, embryonic, fetal, hematopoetic, hemangiogenic, myogenic, nephrogenic, neurogenic, neuralgiagenic, urogenitogenic, osteogenic, pericardiogenic, peritoneogenic, pleurogenic, and splanchogenic, or stromogenic media.

27. The method of claim 25, wherein the morphogenic medium is an adipogenic medium and the cell is monitored to identify adipogenic differentiation.

28. The method of claim 25, wherein the morphogenic medium is a chondrogenic medium and the cell is monitored to identify chondrogenic differentiation.

29. The method of claim 25, wherein the morphogenic medium is an embryonic or fetal medium and the cell is monitored to identify embryonic or fetal phenotype.

30. The method of claim 25, wherein the morphogenic medium is a myogenic medium and the cell is monitored to identify myogenic differentiation.

31. The method of claim 25, wherein the morphogenic medium is an osteogenic medium and the cell is monitored to identify osteogenic differentiation.

32. The method of claim 25, wherein the morphogenic medium is a stromal medium and the cell is monitored to identify stromal or hematopoetic differentiation.

33. The method of claim 25, wherein the cell differentiates in vitro.

34. The method of claim 25, wherein the cell differentiates in vivo.

35. A method of producing hormones, comprising (a) culturing the cell of claim 6 within a medium under conditions sufficient for the cell to secrete the hormone into the medium and (b) isolating the hormone from the medium.

36. A method of promoting the closure of a wound within a patient comprising introducing the cell of claim 6 into the vicinity of a wound under conditions sufficient for the cell to produce the hormone, whereby the presence of the hormone promotes closure of the wound.

37. A method of promoting neovascularization within tissue, comprising introducing the cell of claim 6 into the tissue under conditions sufficient for the cell to produce the hormone, whereby the presence of the hormone promotes neovascularization within the tissue.

38. The method of claim 37, wherein the tissue is within an animal.

39. The method of claim 37, wherein the tissue is a graft.

40. The method of claim 37, wherein the hormone is a growth factor selected from the group of growth factor consisting of human growth factor, nerve growth factor, vascular and endothelial cell growth factor, and members of the TGF.beta. superfamily.

41. A method of conditioning culture medium comprising exposing a cell culture medium to the cell of claim 1 under conditions sufficient for the cell to condition the medium.

42. The method of claim 41, wherein the medium is separated from the cell after it has been conditioned.

43. A conditioned culture medium produced in accordance with the method of claim 41.

44. The conditioned culture medium of claim 43, which is substantially free of lipo-derived stem cells.

45. A method of culturing a stem cell comprising maintaining a stem cell in the conditioned medium of claim 43 under conditions for the stem cell to remain viable.

46. The method of claim 45, which further comprises permitting successive rounds of mitotic division of the stem cell to form an expanded population of stem cells.

47. The method of claim 45, wherein the medium is substantially free of lipo-derived stem cells.

48. The method of claim 45, wherein the medium contains lipo-derived cells.

49. The method of claim 48, wherein a stem cell and a lipo-derived cell are in contact.

50. The method of claim 45, wherein a stem cell is a hemopoetic stem cell.

51. An implant comprising the cell of claim 1.

52. An implant comprising the population of claim 8.

53. A method of isolating stem cells from adipose tissues comprising isolating adipose tissue from a patient and separating stem cells from the remainder of the adipose tissue.

54. The method of claim 53, further comprising differentiating the stem cells.

55. The method of claim 54, wherein the stem cells are differentiated into one or more precursor cell types.

56. The method of claim 55, wherein one or more precursor cell types is selected from the group of precursor cell types consisting of preadipocytes, premyocytes, and preosteocytes.

57. The method of claim 54, wherein the stem cells are differentiated into one or more mature cell types.

58. The method of claim 55, wherein one or more cell types is selected from the group of cell types selected from the group of cell types consisting of adipocytes, chondrocytes, dermal connective tissue cells, hemangial cells tissues, myocytes, osteocytes, neurons, neralglia, urogenital cells, pleural and peritoneal cells, visceral cells, mesodermal glandular cells, and stromal cells.

59. The method of claim 53, wherein the adipose tissue is liposuction effluent.